Rockville, MD. Rise Therapeutics, a biotechnology company developing first-in-class targeted immunological-based biologics using a unique and proprietary oral delivery platform, highlighted today a new publication in the journal Science that highlights mechanisms by which the microbiota engage host immune pathways to improve immunotherapy. The article examines recent pre-clinical studies that found that the peptidoglycan hydrolase Secrete Antigen A (SagA) is able to promote immunotherapy responses and synergize with immune checkpoint inhibitors (ICI) to drive tumor regression in animal model studies. These results support development of novel synthetic biology medicines to be used in conjunction with ICI therapy.
Rockville, MD. Rise Therapeutics today announced that Montgomery County has issued Rise Therapeutics a $25,000 Small Business Innovative Research (SBIR) grant matching award. This funding was awarded based upon Montgomery County’s SBIR/STTR Matching Grant Program and will be used to further Rise Therapeutics’ research project efforts to develop novel microbiome-based medicines,
Rockville, MD. Rise Therapeutics, a synthetic biology company developing targeted immunological-based biologics using a unique and proprietary oral delivery platform, today announced the appointment of Sathya Janardhanan, MS, as Vice President of Development and Manufacturing.
Rockville, MD. Rise Therapeutics announced today that they have received funding associated with the National Institute of Health (NIH) Commercialization Readiness Program (CRP), enabling Rise to establish in house GMP manufacturing capabilities. The NIH’s CRP assists small businesses with technical assistance and late-stage development projects that are not typically supported by SBIR and STTR Phase II and Phase IIB grants or contracts.
Rockville, MD. Rise Therapeutics, a synthetic biology drug development company creating targeted immunological-based biologics using a unique and proprietary oral delivery platform, is pleased to announce the expansion of their executive leadership team. Rise welcomes Christian Furlan Freguia, Ph.D., to the position of Vice President of Research.
Rockville, MD. Rise Therapeutics announced today that they have moved to an Alexandria Real Estate Equities, Inc. (ARE) facility that provides a larger, more effective lab space located in the ARE Maryland life science companies cluster. The mixed laboratory/office space leased by Rise Therapeutics is part of a state-of-the-art research support facility Class A office/lab building located in Rockville, Maryland.